GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Cash Flow from Investing

Immunogen (Immunogen) Cash Flow from Investing : $-1.9 Mil (TTM As of Sep. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Immunogen spent $1.4 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Immunogen spent $1.4 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Immunogen Cash Flow from Investing Historical Data

The historical data trend for Immunogen's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Cash Flow from Investing Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.25 -0.53 0.51 -1.43 -1.36

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 -0.25 -0.21 -0.08 -1.35

Immunogen Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Immunogen's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Immunogen's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunogen  (NAS:IMGN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Immunogen's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $-1.4 Mil. It means Immunogen spent $1.4 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Immunogen's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Immunogen's purchase of business for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Immunogen's sale of business for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Immunogen's purchase of investment for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Immunogen's sale of investment for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Immunogen's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Immunogen's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.0 Mil. It means Immunogen paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Immunogen's cash from other investing activities for the three months ended in Sep. 2023 was $0.0 Mil. It means Immunogen paid $0.0 Mil for other investing activities.


Immunogen Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Immunogen's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451